The North American Neuroendocrine Tumor Society (NANETS) will present the NANETS Clinical Investigator Scholarship at the organization’s 10th annual symposium, to be held October 19-21 in Philadelphia, PA.

The NCI Scholarship supports clinical projects as well as the investigator's potential to make future clinical contributions to the neuroendocrine tumor field and is intended to encourage clinicians’ career development in this area of medicine. The scholarship is supported by IPSEN Biopharmaceuticals in memory of Dr Edda Gomez-Panzani, a NET researcher and advocate who dedicated her life to working with those in need. The two-year award provides $50,000 in funding each year, which is directed to the investigator’s sponsoring institution.

“Ipsen is proud to sponsor the continuation of Edda’s work on behalf of patients with neuroendocrine tumors (NETs) through this Clinical Investigator Scholarship,” said David Cox, PhD, Vice President of Medical and Regulatory Affairs.

“NANETS appreciates the support of Ipsen in providing this important scholarship to promote career development in the neuroendocrine tumor field,” said David Metz, MD, chair of the NANETS Board of Directors. NANETS administers the grant, establishing the criteria and the review process and selecting the recipient.

The North American Neuroendocrine Tumor Society is a society of medical professionals with extensive experience in neuroendocrine tumor (NET) disease. The only one its kind in North America and designed by medical professionals on the front lines of the disease, NANETS is a not-for-profit organization founded in 2007 with the mission of improving neuroendocrine tumor disease management through increased research and educational opportunities.

About Ipsen in North America: Ipsen Biopharmaceuticals, Inc. is the US affiliate of Ipsen, a global specialty-driven biopharmaceutical group. The US head office is located in Basking Ridge, New Jersey. Ipsen has been active in oncology since 1986, branching out from a solid base in prostate, neuroendocrine tumors (NETs), bladder, kidney, pancreatic and breast cancers. Ipsen focuses its resources, investments, and energy on discovering, developing, and commercializing new therapeutic options for oncologic, neurologic, and endocrine diseases. For more information on Ipsen in North America, please visit